Subscribe to MDT Magazine News

CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation

April 18, 2011 6:35 am | by Bio-Medicine.Org | Comments

ATLANTA and IRVINE, Calif., April 18, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis...


Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient

April 18, 2011 6:34 am | by Bio-Medicine.Org | Comments

GAITHERSBURG, Md., April 18, 2011 /- Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase)....


InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market

April 18, 2011 6:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, April 18, 2011 /- InstaCare Corp. (OTCQB: ISCR) a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e...


Community Health makes all-cash bid for Tenet

April 18, 2011 4:45 am | by The Associated Press | Comments

Hospital operator Community Health Systems Inc. is revising its $3 billion offer for rival Tenet Healthcare Corp. to an all-cash bid.The offer values Tenet at $6 per share. In December, Community Health Systems went public with a bid of $5 per share in cash and $1 per share in stock. At the...

University of Virginia Installs First Two TomoTherapy(R) TomoHD(TM) Systems in U.S.

April 18, 2011 4:45 am | by The Associated Press | Comments () —TomoTherapy Incorporated ( (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that two of the first TomoTherapy@ TomoHD treatment systems in the United States...

Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011

April 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

ANAHEIM, Calif., April 18, 2011 /- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced that it will release first quarter 2011 financial results on Tuesday, April 26, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast...


Lilly Reports First-Quarter 2011 Results

April 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, April 18, 2011 /- First quarter 2011 revenue grew 6 percent to $5.8 billion, driven by increased demand in international markets. Company delivered first quarter earnings per share of $.95 (reported), or $1.24 (non-GAAP). 2011 non-GAAP earnings per share guidance range...


PDL BioPharma to Hold Annual Meeting of Stockholders on June 22, 2011

April 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

INCLINE VILLAGE, Nev., April 18, 2011 /- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. Pacific Time for all stockholders of record on April 25, 2011. The meeting will take...


Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors

April 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, April 18, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today filed a revised preliminary consent solicitation statement in which it named Mr. Abe M. Friedman to its slate of proposed directors in connection with its previously announced...


TRTB to Launch Blue Diamond Pill Targeting Ethnic Market With Sexual Enhancement Pills

April 18, 2011 2:36 am | by Bio-Medicine.Org | Comments

LOS ANGELES, April 18, 2011 /- True 2 Beauty Inc., (Pinksheets: TRTB - News ) (the "Company") ( ), a leading distributor of male and female sexual potency pills and liquid products in the United States, is pleased to announce the launch of a new, additional line of...


Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C

April 18, 2011 12:35 am | by Bio-Medicine.Org | Comments

BLUE BELL, Pa., April 18, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (Euronext Paris:...


$210M Pfizer Deal Validates Small Firm

April 17, 2011 11:33 pm | by San Diego Business Journal | Comments

Robin Jackman, Zacharon's president and CEO, is the first to admit that there aren't too many people outside the biotech world who understand the science at the core of his small company.


Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S...

April 17, 2011 10:34 pm | by Bio-Medicine.Org | Comments

MYSTIC, Conn. and DUBLIN, April 18, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product...


Minorities born with heart defects at higher risk of dying in early childhood than whites

April 17, 2011 9:32 pm | by EurekAlert | Comments

(University of South Florida (USF Health)) Non-Hispanic black infants born with heart defects are more likely to die within the first five years of life than their non-Hispanic white and Hispanic peers, reports a new study by researchers at the University of South Florida, Texas...


High-Speed Evolution Aids Drug Development

April 17, 2011 8:36 pm | by Massachusetts Institute of Technology | Comments

A new technique can make tailor-made proteins evolve in days, not years.


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.